Urogen Pharma (NASDAQ:URGN) Given Average Rating of “Moderate Buy” by Brokerages

Urogen Pharma (NASDAQ:URGN) has been given an average recommendation of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $36.6667.

A number of research analysts have commented on URGN shares. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the period. State of Wyoming purchased a new position in Urogen Pharma during the 3rd quarter valued at about $66,000. Russell Investments Group Ltd. boosted its holdings in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares during the period. Osaic Holdings Inc. raised its position in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Stock Up 1.5%

Shares of Urogen Pharma stock opened at $27.25 on Tuesday. Urogen Pharma has a 52 week low of $6.64 and a 52 week high of $32.37. The business’s fifty day simple moving average is $24.84 and its 200-day simple moving average is $22.75. The firm has a market cap of $1.33 billion, a PE ratio of -9.91 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. As a group, equities analysts expect that Urogen Pharma will post -0.98 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.